9,533 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Acquired by Arizona State Retirement System

Arizona State Retirement System bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the fourth quarter, HoldingsChannel reports. The firm bought 9,533 shares of the company’s stock, valued at approximately $208,000.

A number of other large investors have also bought and sold shares of VRDN. Alliancebernstein L.P. bought a new stake in Viridian Therapeutics during the 4th quarter worth approximately $26,985,000. State Street Corp increased its stake in Viridian Therapeutics by 159.0% during the 3rd quarter. State Street Corp now owns 1,178,549 shares of the company’s stock worth $24,172,000 after purchasing an additional 723,484 shares in the last quarter. BlackRock Inc. increased its stake in Viridian Therapeutics by 39.3% during the 3rd quarter. BlackRock Inc. now owns 1,982,062 shares of the company’s stock worth $40,653,000 after purchasing an additional 559,238 shares in the last quarter. Braidwell LP increased its stake in Viridian Therapeutics by 43.8% during the 3rd quarter. Braidwell LP now owns 1,735,182 shares of the company’s stock worth $26,618,000 after purchasing an additional 528,882 shares in the last quarter. Finally, Perceptive Advisors LLC increased its stake in Viridian Therapeutics by 42.3% during the 1st quarter. Perceptive Advisors LLC now owns 1,736,386 shares of the company’s stock worth $44,174,000 after purchasing an additional 515,811 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on VRDN shares. B. Riley lowered their target price on Viridian Therapeutics from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, March 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 price target on shares of Viridian Therapeutics in a research report on Wednesday, March 20th. Wedbush upped their price target on Viridian Therapeutics from $39.00 to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Viridian Therapeutics in a research report on Thursday, February 29th. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat, Viridian Therapeutics currently has an average rating of “Buy” and an average target price of $36.60.

Viridian Therapeutics Trading Down 3.7 %

NASDAQ VRDN opened at $14.60 on Monday. The company has a market cap of $916.44 million, a PE ratio of -2.74 and a beta of 1.07. The company has a current ratio of 18.26, a quick ratio of 18.26 and a debt-to-equity ratio of 0.09. Viridian Therapeutics, Inc. has a 12 month low of $10.93 and a 12 month high of $30.30. The stock has a 50 day moving average of $17.70 and a 200-day moving average of $17.55.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.37). The company had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.15 million. Viridian Therapeutics had a negative net margin of 75,711.48% and a negative return on equity of 121.80%. The company’s quarterly revenue was down 31.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.13) EPS. On average, equities research analysts anticipate that Viridian Therapeutics, Inc. will post -4.39 EPS for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.